Last reviewed · How we verify
Infanrix (infanrix)
Infanrix is a marketed vaccine by Pfizer Inc. It protects against diphtheria, tetanus, and pertussis in infants and children. The vaccine contains diphtheria and tetanus toxoids, and either killed whole cells of the bacterium that causes pertussis or pertussis antigens. This combination provides broad protection against these infectious diseases. Infanrix has a generic version with multiple manufacturers, indicating a well-established market presence. The vaccine's mechanism is based on inactivated toxins to generate an immune response. Its commercial significance lies in its widespread use for infant and childhood vaccinations.
At a glance
| Generic name | infanrix |
|---|---|
| Sponsor | Pfizer |
| Drug class | vaccine |
| Modality | Vaccine |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- Prevention of diphtheria, tetanus, and pertussis in infants and children aged 6 weeks through 6 years
Common side effects
- Irritability/Fussiness, any
- Drowsiness, any
- Pain, any (Dose 4)
- Redness, any (Dose 4)
- Swelling, any (Dose 4)
- Loss of appetite, any
- Fever (≥100.4°F)
- Redness, any (Dose 3)
- Pain, any (Dose 4 booster)
- Swelling, any (Dose 3)
- Increase in mid-thigh circumference, any
- Drowsiness, Grade 2 or 3
Drug interactions
- Live vaccines
- Immune globulins
- Blood products
- Other vaccines
- Interferon
- Immunosuppressive drugs
Key clinical trials
- Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (PHASE4)
- Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy (PHASE4)
- Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine (PHASE1, PHASE2)
- BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies (PHASE3)
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (PHASE2)
- Immunogenicity of 2 Versus 3 Doses of Combined Hepatitis B Vaccines in 2-18 Months Old Children (PHASE4)
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
- Maternal Determinants of Infant Immunity to Pertussis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Infanrix CI brief — competitive landscape report
- Infanrix updates RSS · CI watch RSS
- Pfizer portfolio CI